Abbott's Q4 Molecular Dx Sales Rise 21 Percent

The firm's US MDx sales rose 32 percent for the quarter and 27 percent for the year. Abbott also announced a restructuring for its pharma business.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories